Fig. 3From: Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapyTreatment process and outcomes. A The whole treatment process for five patients from CART1 infusion to the cut-off time. Each bar's color and length represent the status and duration of the response, respectively. Pt04 received salvage transplantation after CART2. B Kaplan–Meier curves of event-free survival (EFS) and overall survival (OS) probabilities in CART2. C The detailed treatment process of 5 patients, including the time and result of BM aspiration, the scheme of lymphodepletion chemotherapy, and the time of CAR-T infusion. D In pt03, the proportion of leukemia cells changed from MRD 8.9% on day − 7 to MRD < 0.01% on day 26 and remained at MRD < 0.01% on day 322 after CART2 (post HSCT)Back to article page